DEERFIELD, Ill.--(BUSINESS WIRE)--TerSera Therapeutics LLC announced today the presentation of new real-world analyses on the treatment patterns of goserelin in women with breast cancer. The data were ...

Goserelin (as acetate) 10.8mg; SC implant. Zoladex is a synthetic decapeptide analogue of GnRH. It acts as an inhibitor of pituitary gonadotropin secretion when administered in the biodegradable ...

Injection site injury and vascular injury including pain, hematoma, hemorrhage and hemorrhagic shock, requiring blood transfusions and surgical intervention, have been reported with ZOLADEX. Extra ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. A drug that reduces the amount of estrogen in the body can help prevent ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...

WASHINGTON, May 30 (UPI) --The drug goserelin, sold by AstraZeneca under the brand name Zoladex, may help protect the ovaries of women with breast cancer. "It's not a panacea, but based on these data, ...

AstraZeneca today announced plans to invest £120 million ($190 million) in a new facility at its global manufacturing site in Macclesfield, UK, to continue production of Zoladex, an injectable ...